EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ticagrelor reduces doxorubicin-induced pyroptosis of rat cardiomyocytes by targeting GSK-3β/caspase-1

Shu-Hui Wang, Meng-Jin Sun, Si-Yue Ding, Chun-Li Liu, Jing-Min Wang, Sheng-Na Han, Xi Lin, Qian Li

Frontiers in Cardiovascular Medicine · 06.01.2023 · 9

DOI: 10.3389/fcvm.2022.1090601 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 06.01.2023. Verfasst von Shu-Hui Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasound, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Henan Provincial Science and Technology Research Project, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Doxorubicin (Dox) is a widely used clinical drug whose cardiotoxicity cannot be ignored. Pyroptosis (inflammatory cell death) has gradually gained attention in the context of Dox-induced cardiotoxicity. In addition to the inhibition of platelet activation by ticagrelor, little is known about its other pharmacological effects. Glycogen synthase kinase 3β (GSK-3β) has been shown to contribute to the pathological process of pyroptosis, but whether it is related to the potential role of ticagrelor is unclear. In this study, we investigated the effects of ticagrelor on Dox-induced pyroptosis in cardiomyocytes. Rats were treated with ticagrelor (7.5 mg/kg, i.g.) 1 h before intravenous injection of Dox (2.5 mg/kg), once every 3 days, six times in total. Hearts were collected for histochemical analysis and western blot detection 8 weeks after the last administration. Ticagrelor was shown to significantly improve cardiac function by inhibiting GSK-3β/caspase-1/GSDMD activation. In vitro experiments were conducted using rat cardiac myocytes (RCMs) and rat embryonic cardiac-derived H9c2 cells. Pretreatment with ticagrelor (10 μm) significantly inhibited Dox (1 μm)-induced hypertrophy and reversed the upregulation of GSDMD-NT expression. We showed that ticagrelor suppressed the activation of Akt caused by Dox in the heart tissue as well as in RCMs/H9c2 cells caused by Dox. When GSK-3β expression was absent in H9c2 cells, the inhibitory effect of ticagrelor on Dox-induced caspase-1/GSDMD activation was weakened. These data showed that ticagrelor reduced Dox-induced pyroptosis in rat cardiomyocytes by targeting GSK-3β/caspase-1.

Schlagwörter

Stichwörter der Autor:innen

GSK-3βcaspase-1doxorubicinpyroptosisticagrelor

Autor:innen und Institutionen

  • Department of Ultrasound, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
  • Department of Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.
  • State Key Laboratory of Oncology in South China, Department of Ultrasound, Sun Yat-sen University Cancer Center, Guangzhou, China.

Förderung

  • Henan Provincial Science and Technology Research Project
  • National Natural Science Foundation of China

Zitieren

APA

Wang, S. H., Sun, M. J., Ding, S. Y., Liu, C. L., Wang, J. M., Han, S. N., Lin, X., & Li, Q. (2023). Ticagrelor reduces doxorubicin-induced pyroptosis of rat cardiomyocytes by targeting GSK-3β/caspase-1. Frontiers in Cardiovascular Medicine, 9. https://doi.org/10.3389/fcvm.2022.1090601

Vancouver

Wang SH, Sun MJ, Ding SY, Liu CL, Wang JM, Han SN, et al. Ticagrelor reduces doxorubicin-induced pyroptosis of rat cardiomyocytes by targeting GSK-3β/caspase-1. Frontiers in Cardiovascular Medicine. 2023;9. doi:10.3389/fcvm.2022.1090601

BibTeX
@article{Wang2023,
  author = {Wang, Shu-Hui and Sun, Meng-Jin and Ding, Si-Yue and Liu, Chun-Li and Wang, Jing-Min and Han, Sheng-Na and Lin, Xi and Li, Qian},
  title = {Ticagrelor reduces doxorubicin-induced pyroptosis of rat cardiomyocytes by targeting GSK-3β/caspase-1},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2023},
  volume = {9},
  doi = {10.3389/fcvm.2022.1090601}
}
Kostenlos starten →